Kidney Cancer Drugs Global Market Report 2025

Description

Kidney cancer drugs are designed to treat kidney cancer through systemic therapy, reaching cancer cells throughout the body. Various medications may be employed, depending on the type of kidney cancer. These drugs work by targeting key proteins, such as tyrosine kinases, crucial for the growth and survival of cancer cells, or by inhibiting angiogenesis, the formation of new blood vessels that nourish tumors.

The main types of kidney cancer include renal cell carcinoma (RCC), urothelial carcinoma, and others (renal sarcoma, renal lymphoma). Renal cell carcinoma is a condition where malignant cells form in the kidney's tubules. Different products involved in treating kidney cancer include Nexavar (sorafenib), Sutent (sunitinib), Afinitor (everolimus), Voting (pazopanib), Avastin (bevacizumab), Inlyta (axitinib), Torisel (temsirolimus), Proleukin (aldesleukin), and others. These drugs are used by hospitals, clinics, research centers, and similar healthcare facilities.

The kidney cancer drugs market research report is one of a series of new reports from The Business Research Company that provides kidney cancer drugs market statistics, including kidney cancer drugs industry global market size, regional shares, competitors with a kidney cancer drugs market share, detailed kidney cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the kidney cancer drugs industry. This kidney cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The kidney cancer drugs market size has grown strongly in recent years. It will grow from $8.2 billion in 2024 to $8.63 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to increased healthcare expenditure, rapid growth in elderly population, increase in pharmaceutical R&D expenditure, and advances in cancer drug discovery.

The kidney cancer drugs market size is expected to see steady growth in the next few years. It will grow to $10.48 billion in 2029 at a compound annual growth rate (CAGR) of 5.0%. The growth in the forecast period can be attributed to increasing geriatric population, rise in healthcare expenditure, rise in acquisitions and partnerships for drug development, and high potential of emerging economies. Major trends in the forecast period include adopting 3D technology in manufacturing drugs and create models, investing in biomarkers, launching or adopting new treatment developments, improve treatment by offering personalized medicine, invest in ai solutions, and collaborating and partnering with other companies or government bodies to accelerate the development of new drugs.

The surge in the incidence of renal cancer stands out as a significant driver of the kidney cancer drugs market. Lifestyle changes, tobacco consumption, and an unhealthy diet contribute to the proliferation of renal cancer cells. For example, the American Cancer Society reported in January 2022 that approximately 79,000 new cases of kidney cancer (50,290 in men and 28,710 in women) are expected to be diagnosed, resulting in 13,920 fatalities (8,960 in men and 4,960 in women). The majority of diagnoses occur between the ages of 65 and 74, with an average age of diagnosis being 64. Kidney cancer is relatively rare in individuals under the age of 45, emphasizing the driving force behind the growth of the kidney cancer drugs market.

Government initiatives and funding addressing kidney disorders are anticipated to propel the kidney cancer drugs market's growth. Government initiatives and funding provide financial support to entities and projects contributing to public services and the economy. These initiatives enhance disease surveillance, raise awareness, and promote research in kidney disorders. For instance, in July 2022, the United States House Committee on Appropriations initiated investment programs to boost kidney health. This includes $8.5 million in funding for the Centers for Disease Control and Prevention's chronic kidney disease program, aimed at promoting awareness, diagnosis, and treatment. Additionally, a living donation investment of $1 million was allocated to the national living donor assistance center, bringing the total to $8 million for innovation and research. Consequently, government initiatives and funding for kidney disorders play a pivotal role in driving the kidney cancer drugs market's growth.

Leading companies in the kidney cancer drugs market are prioritizing technologies like biosimilar development to expand treatment options, increase patient access to affordable therapies, and drive innovation in cancer care. Biosimilar development involves creating biological drugs that closely resemble an already approved reference product, offering comparable efficacy, safety, and quality. For example, in November 2022, Amneal Pharmaceuticals Inc., a US-based pharmaceutical company, launched RELEUKO (filgrastim-ayow), a biosimilar to Neupogen (filgrastim), developed to treat neutropenia, particularly in patients undergoing chemotherapy.

Leading companies in the kidney cancer drugs market are also focused on technologies like shelf stability to extend product longevity, improve storage convenience, and provide reliable access to essential treatments for patients and healthcare providers. Shelf stability technology includes formulations and packaging strategies that increase the shelf life of pharmaceuticals without the need for refrigeration or special handling. This approach ensures drugs remain effective and safe over a longer period, enhancing storage and distribution convenience. For instance, in April 2024, Amneal Pharmaceuticals Inc., a US-based pharmaceutical company, introduced PEMRYDI RTU, the first ready-to-use version of pemetrexed for injection that requires no reconstitution, dilution, or refrigeration, streamlining preparation for healthcare providers.

In October 2022, LG Chem, Ltd. acquired AVEO Oncology for $566 million. This acquisition positions LG Chem's Life Sciences Division in the U.S., diversifies its pipeline with various oncology treatments, and accelerates LG Chem's growth efforts in the oncology sector. The collaboration aims to establish a global oncology organization with a robust portfolio, spanning from discovery to clinical development, biologics manufacturing, and U.S. commercialization, ultimately broadening access to treatment options. AVEO Oncology is a U.S.-based biopharmaceutical company committed to delivering cancer patients drugs that enhance their quality of life.

Major companies operating in the kidney cancer drugs market include Pfizer Inc., Novartis AG, ExelixisInc., F. Hoffmann-La Roche AG, Bristol Myers Squibb Company, Bayer AG, Merck & Co., Inc., EUSA Pharma Inc., UroGen Pharma Ltd., Natco Pharma, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc, Otsuka Pharmaceutical Co., Ltd, Daiichi Pharmaceutical and Sankyo, AstraZeneca plc, GlaxoSmithKline plc, Amgen Inc., Biocon Ltd, Rani Therapeutics, Eli Lilly and Company, Abbvie, Johnson & Johnson, Sanofi, Biogen Inc, AVEO Oncology, Teva Pharmaceutical Industries Ltd., Kitov Pharma Limited, CureTech Ltd., Neopharma

North America was the largest region in the kidney cancer drugs market in 2024. Middle East is expected to be the fastest-growing region in the global kidney cancer drugs market share during the forecast period. The regions covered in the kidney cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the kidney cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The kidney cancer drugs market consists of sales of axitinib (Inlyta), cabozantinib (cabometyx), and pazopanib. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Kidney Cancer Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on kidney cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for kidney cancer drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The kidney cancer drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Renal Cell Carcinoma (RCC), Transitional Cell Carcinoma (TCC) Or Urothelial Cell Carcinoma (UCC)
2) By Product: Nexavar (Sorafenib), Sutent (Sunitinib), Afinitor (Everolimus), Votrient (Pazopanib), Avastin (Bevacizumab), Inlyta (Axitinib), Other Products
3) By End Users: Hospitals, Clinics, Research Center, Other End-Users
Subsegments:
1) By Renal Cell Carcinoma (RCC): Targeted Therapies; Immune Checkpoint Inhibitors; Cytokine Therapies
2) By Transitional Cell Carcinoma (TCC) Or Urothelial Cell Carcinoma (UCC): Chemotherapy Agents; Immunotherapy Agents; Antibody-Drug Conjugates (ADCs)
Companies Mentioned: Pfizer Inc.; Novartis AG; ExelixisInc.; F. Hoffmann-La Roche AG; Bristol Myers Squibb Company
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r25736

1. Executive Summary

2. Kidney Cancer Drugs Market Characteristics

3. Kidney Cancer Drugs Market Trends And Strategies

4. Kidney Cancer Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Kidney Cancer Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Kidney Cancer Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Kidney Cancer Drugs Market Growth Rate Analysis
5.4. Global Kidney Cancer Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Kidney Cancer Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Kidney Cancer Drugs Total Addressable Market (TAM)

6. Kidney Cancer Drugs Market Segmentation

6.1. Global Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Renal Cell Carcinoma
Transitional Cell Carcinoma (TCC) Or Urothelial Cell Carcinoma (UCC)
6.2. Global Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Nexavar (Sorafenib)
Sutent (Sunitinib)
Afinitor (Everolimus)
Votrient (Pazopanib)
Avastin (Bevacizumab)
Inlyta (Axitinib)
Other Products
6.3. Global Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Research Center
Other End-Users
6.4. Global Kidney Cancer Drugs Market, Sub-Segmentation Of Renal Cell Carcinoma (RCC), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Targeted Therapies
Immune Checkpoint Inhibitors
Cytokine Therapies
6.5. Global Kidney Cancer Drugs Market, Sub-Segmentation Of Transitional Cell Carcinoma (TCC) Or Urothelial Cell Carcinoma (UCC), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chemotherapy Agents
Immunotherapy Agents
Antibody-Drug Conjugates (ADCs)

7. Kidney Cancer Drugs Market Regional And Country Analysis

7.1. Global Kidney Cancer Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Kidney Cancer Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Kidney Cancer Drugs Market

8.1. Asia-Pacific Kidney Cancer Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Kidney Cancer Drugs Market

9.1. China Kidney Cancer Drugs Market Overview
9.2. China Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Kidney Cancer Drugs Market

10.1. India Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Kidney Cancer Drugs Market

11.1. Japan Kidney Cancer Drugs Market Overview
11.2. Japan Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Kidney Cancer Drugs Market

12.1. Australia Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Kidney Cancer Drugs Market

13.1. Indonesia Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Kidney Cancer Drugs Market

14.1. South Korea Kidney Cancer Drugs Market Overview
14.2. South Korea Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Kidney Cancer Drugs Market

15.1. Western Europe Kidney Cancer Drugs Market Overview
15.2. Western Europe Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Kidney Cancer Drugs Market

16.1. UK Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Kidney Cancer Drugs Market

17.1. Germany Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Kidney Cancer Drugs Market

18.1. France Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Kidney Cancer Drugs Market

19.1. Italy Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Kidney Cancer Drugs Market

20.1. Spain Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Kidney Cancer Drugs Market

21.1. Eastern Europe Kidney Cancer Drugs Market Overview
21.2. Eastern Europe Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Kidney Cancer Drugs Market

22.1. Russia Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Kidney Cancer Drugs Market

23.1. North America Kidney Cancer Drugs Market Overview
23.2. North America Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Kidney Cancer Drugs Market

24.1. USA Kidney Cancer Drugs Market Overview
24.2. USA Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Kidney Cancer Drugs Market

25.1. Canada Kidney Cancer Drugs Market Overview
25.2. Canada Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Kidney Cancer Drugs Market

26.1. South America Kidney Cancer Drugs Market Overview
26.2. South America Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Kidney Cancer Drugs Market

27.1. Brazil Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Kidney Cancer Drugs Market

28.1. Middle East Kidney Cancer Drugs Market Overview
28.2. Middle East Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Kidney Cancer Drugs Market

29.1. Africa Kidney Cancer Drugs Market Overview
29.2. Africa Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Kidney Cancer Drugs Market Competitive Landscape And Company Profiles

30.1. Kidney Cancer Drugs Market Competitive Landscape
30.2. Kidney Cancer Drugs Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. ExelixisInc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Kidney Cancer Drugs Market Other Major And Innovative Companies

31.1. Bayer AG
31.2. Merck & Co., Inc.
31.3. EUSA Pharma Inc.
31.4. UroGen Pharma Ltd.
31.5. Natco Pharma
31.6. CStone Pharma
31.7. CARsgen Therapeutics
31.8. JW Therapeutics
31.9. BeiGene
31.10. Takeda Pharmaceuticals
31.11. Astellas Pharma Inc
31.12. Otsuka Pharmaceutical Co., Ltd
31.13. Daiichi Pharmaceutical and Sankyo
31.14. AstraZeneca plc
31.15. GlaxoSmithKline plc

32. Global Kidney Cancer Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Kidney Cancer Drugs Market

34. Recent Developments In The Kidney Cancer Drugs Market

35. Kidney Cancer Drugs Market High Potential Countries, Segments and Strategies

35.1 Kidney Cancer Drugs Market In 2029 - Countries Offering Most New Opportunities
35.2 Kidney Cancer Drugs Market In 2029 - Segments Offering Most New Opportunities
35.3 Kidney Cancer Drugs Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer